DONANEMAB AND LECANEMAB

  • Two drugs to treat Alzheimer’s disease showed promising results.
  • Alzheimer’s disease is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die.
  • Alzheimer’s disease is the most common cause of dementia — a continuous decline in thinking, behavioral and social skills that affects a person’s ability to function independently.
  • The early signs of the disease include forgetting recent events or conversations.
  • As the disease progresses, a person with Alzheimer’s disease will develop severe memory impairment and lose the ability to carry out everyday tasks.
  • There is no treatment that cures Alzheimer’s disease or alters the disease process in the brain.
  • Alzheimer’s disease affects at least 55 million people worldwide.
  • Alzheimer’s disease is the most common form of dementia.
  • Dementia is the seventh leading cause of death and one of the major causes of disability and dependency among older people globally.

The drugs:

  • As with similar antibody-based therapies such as lecanemab, donanemab is not a cure for Alzheimer’s.
  • Instead, they are antibodies that target different forms of amyloid-beta (Aβ) proteins that can clump together to form amyloid plaques in people’s brains, resulting in their congnitive decline.
  • The drug aims to remove the plaques from the brain and slow the progression of the disease.

SOURCE: THE HINDU, THE ECONOMIC TIMES, PIB

About sree nivas

Check Also

Balanced Fertilization and the Path Forward

Introduction Balanced fertilization is a crucial aspect of sustainable agriculture, aiming to provide crops with …

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Free Updates to Crack the Exam!
Subscribe to our Newsletter for free daily updates